Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study ; volume:271 ; number:10 ; day:4 ; month:9 ; year:2024 ; pages:6956-6969 ; date:10.2024
Journal of neurology ; 271, Heft 10 (4.9.2024), 6956-6969, 10.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-024-12665-x
- URN
-
urn:nbn:de:101:1-2412192150334.756951526378
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chalitsios, Christos V.
- Ley, Harriet
- Gao, Jiali
- Turner, Martin R.
- Thompson, Alexander G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease
Longitudinal associations between use of antihypertensive, antidiabetic, and lipid-lowering medications and biological aging
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study
Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?